You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Pfizer, Flynn accused of charging the NHS ‘unfairly high prices’ for anti-epilepsy drug

Pfizer and Flynn have been accused of breaking competition law by overcharging the NHS for ‘vital’ anti-epilepsy drugs, according to provisional findings from the UK Competition and Markets Authority (CMA).